《大行報告》美銀證券:華潤置地(01109.HK)迎來多個正面因素 屬內房股首選之一
美銀發表研究報告指,華潤置地(01109.HK)迎來多個正面因素,為內房股首選之一。即將推出深圳華潤城第四期項目,涉及逾1,170伙,可售面積23.8萬平方呎,預期可帶動12月份銷售額按年增長雙位數,估計若銷售可於年內入帳,項目毛利率高達60%更可為全年推動毛利率水平。
報告指出,深圳華潤城過往銷情熱烈,買家中籤率僅10%至14%,去化率達百分之百,估計第四期項目可帶來約300億元人民幣的合約銷售額。另外,該行預期受今年下半年租務活躍支持,潤地明年租賃收入可增長18%。
該行預期,公司正在探索購股權計劃,料可激勵管理層及員工,對公司長遠發展有利,考慮到估值吸引,較每股資產淨值折讓約35%,維持「買入」評級,目標價43元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.